In Q1, 2017, the fund invested in Clinical Ink, which is one of Winston Salem's best startup companies. The press release below gives an overview of the company's progress.
Clinical Ink Reports Record Contract Signings in Q3 2016 – $16M in Bookings
PHILADELPHIA, PA & CAMBRIDGE, MA – October 21, 2016 – Clinical Ink, the pioneering provider of eSource and patient engagement technologies for clinical trials, today announced record quarterly contract bookings of $16M in the third quarter of 2016.
“These results demonstrate that the market is ready for eSource adoption now,” said Ed Seguine, CEO, Clinical Ink. “Demand for our eSource platform has been broad-based across large pharma, biotech, and CROs. Early adopters are realizing dramatic improvements – closing their study databases 23 hours after the last patient visit, reducing data management and monitoring costs by more than 25%, and gaining unparalleled insight and visibility into protocol execution by the sites. We see interest continuing to accelerate as the industry recognizes that eSource provides a better experience for sites, patients and sponsors than the current EDC model permits.”
Recent highlights include:
- Record YTD contract bookings – increase of 275% versus 2015
- The largest single study contract for a 14,000 patient Phase III vaccine study
- New Patient Engagement and Data Management products account for 50% of YTD bookings
- The SureSource platform surpassed 8,300 users in 50 countries
“Clinical Ink’s technology does far more than simply change the way source documents and data are captured,” said Jonathan Andrus, Chief Data Officer, Clinical Ink. “The use of SureSource at the critical moment during a patient visit or directly by patients dramatically improves protocol execution. As the only platform that combines both data and documents, SureSource re-defines what Risk-Based Monitoring and Data Management means by focusing on the source data and source documents that matter most.”
Since its commercial launch in 2012, Clinical Ink has emerged as an innovation leader with its eSource and patient engagement platform. The SureSource platform eliminates the need for separate EDC, eCOA, and ePRO applications while reducing the cost, complexity, and time associated with data management and monitoring activities. SureSource collects documents and data from sites and patients in real time, providing sponsors with timely, data-based insights into protocol execution, data quality, trial surveillance, and GCP compliance that are impossible with legacy EDC/eCOA/ePRO systems and current practices.
About Clinical Ink
Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier for sites, sponsors and patients. Clinical Ink’s SureSource® comprehensive platform directly captures eSource data and documents and improves patient engagement by focusing on the critical moments that matter when executing the protocol. Clinical Ink maintains offices in Cambridge, MA, Winston-Salem, NC, and Philadelphia, PA. Find more at www.clinicalink.com.